Healthcare
Wednesday, September 7, 2016
BRIEF-Retrophin announces results from phase 2 duet study of sparsentan
* Line results from Phase 2 DUET study of sparsentan in
patients with focal segmental glomerulosclerosis
Read more
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment